Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Anti-Myeloma Activity of LDC-000067, a Novel Selective Inhibitor of Cyclin Dependent Kinase 9: A Targeted Approach

Kathrin Niepoth, Dirk Gustavus, Doris Wenning, Michael Meisterernst, Joachim Kienast, Wolfgang E. Berdel, Guido Bisping

Blood (2011) 118 (21): 5110.

https://doi.org/10.1182/blood.V118.21.5110.5110

Published: 2011

Journal Articles

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups

Guido Bisping, Martin Kropff, Doris Wenning, Britta Dreyer, Sergey Bessonov, Frank Hilberg, Gerald J. Roth, Gerd Munzert, Martin Stefanic, Matthias Stelljes, Christian Scheffold, Carsten Müller-Tidow, Peter Liebisch, Nicola Lang, Jöelle Tchinda, Hubert L. Serve, Rolf M. Mesters, Wolfgang E. Berdel, Joachim Kienast

Blood (2006) 107 (5): 2079–2089.

https://doi.org/10.1182/blood-2004-11-4250

Published: 2006

Journal Articles

Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.

Guido Bisping, MD, Doris Wenning, Martin H. Kropff, MD, Gerd Munzert, MD, Frank Hilberg, PhD, Gerald J. Roth, PhD, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2005) 106 (11): 112.

https://doi.org/10.1182/blood.V106.11.112.112

Published: 2005

Journal Articles

Bortezomib in Combination with Dexamethasone for Relapsed Multiple Myeloma.

Martin H. Kropff, MD, Guido Bisping, MD, Doris Wenning, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2004) 104 (11): 4923.

https://doi.org/10.1182/blood.V104.11.4923.4923

Published: 2004

Journal Articles

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma

Guido Bisping, Regine Leo, Doris Wenning, Berno Dankbar, Teresa Padró, Martin Kropff, Christian Scheffold, Matthias Kröger, Rolf M. Mesters, Wolfgang E. Berdel, Joachim Kienast

Blood (2003) 101 (7): 2775–2783.

https://doi.org/10.1182/blood-2002-09-2907

Published: 2003

NARROW

Anti-Myeloma Activity of LDC-000067, a Novel Selective Inhibitor of Cyclin Dependent Kinase 9: A Targeted Approach

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups

Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.

Bortezomib in Combination with Dexamethasone for Relapsed Multiple Myeloma.

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Anti-Myeloma Activity of LDC-000067, a Novel Selective Inhibitor of Cyclin Dependent Kinase 9: A Targeted Approach

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups

Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.

Bortezomib in Combination with Dexamethasone for Relapsed Multiple Myeloma.

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only